<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654703</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-2015-AML</org_study_id>
    <nct_id>NCT03654703</nct_id>
  </id_info>
  <brief_title>Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML</brief_title>
  <official_title>Improved Post-Transplant Cyclophosphamide Regimens for Unmanipulated Haploidentical Transplant in Pediatric Patients With Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Research Institute of Pediatrics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Research Institute of Pediatrics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory
      acute myeloid leukemia (R-AML）patients. Investigators reasoned that this group of patients if
      they have been treated with ablative conditioning regimens for HSCT combined with PT/Cy,
      under the rapid of immune reconstitution will have better outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haploidentical stem cell transplantation (HSCT) is a potentially curative therapy for
      patients with high risk or refractory acute myeloid leukemia (R-AML). Graft-versus-host
      disease （GVHD）is a major barrier to achieve success for patients with HSCT. High dose
      cyclophosphamide given after HLA-matched related and unrelated allogeneic stem cell
      transplantation for patients with hematologic malignancies is effective single agent (GVHD)
      prophylaxis in adults and in pediatric benign patients. Data describing outcomes for
      pediatric maligant patients has not been reported. Investigators have recruited 26 pediatric
      patients (3 years &lt; age &lt;18 years) between March 2015 to July 2018 with primary induction
      R-AML treated in investigators' institution for R-AML with modified myeloablative regimen,
      post-transplant cyclophosphamide (PTCy) has been used as GVHD prophylaxis.

      Conditioning regimen of the group of patient consisted Idrabine(IDA,10mg/m2/day) which was
      administered intravenously for 2 days, from days -14 to -13, total body irritation (TBI, 9
      Gy) which was divided into 3 fractions and 3 days from -12 to -10, thymoglobulin
      (2.5mg/kg/day) was administered for 3 days, from -9 to -7, etoposide (VP-16, 300mg/m2) which
      was infused intravenously on day -6, cladribine (10mg/m2/day) which was administered for 3
      days from -5 to -2 .
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 1, 2015</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">July 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease status</measure>
    <time_frame>1 year</time_frame>
    <description>Disease status can be measured by test the of (minimal residual disease) MRD via flow cytometry one time each month until one year after HSCT. MRD&lt;0.0001 （complete remission), if not, relapse.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hematopoietic System--Cancer</condition>
  <arm_group>
    <arm_group_label>Cyclophophamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>cyclophophamide</description>
    <arm_group_label>Cyclophophamide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -refractory AML

        Exclusion Criteria:

        - complete remission AML
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Y Qin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hematology and oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yan Yue</name>
      <address>
        <city>Beijing</city>
        <state>Chaoyang District</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, Furukawa T, Nara M, Akashi K, Taniguchi S, Harada M, Matsuo K, Teshima T; Japan Study Group for Cell Therapy and Transplantation (JSCT). Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2019 Mar;54(3):432-441. doi: 10.1038/s41409-018-0279-1. Epub 2018 Aug 7.</citation>
    <PMID>30087460</PMID>
  </results_reference>
  <results_reference>
    <citation>Marani C, Raiola AM, Morbelli S, Dominietto A, Ferrarazzo G, Avenoso D, Giannoni L, Varaldo R, Gualandi F, Grazia D, Lamparelli T, Bregante S, Van Lint MT, Ibatici A, Bovis F, Lemoli RM, Gobbi M, Bacigalupo A, Angelucci E. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Biol Blood Marrow Transplant. 2018 Dec;24(12):2501-2508. doi: 10.1016/j.bbmt.2018.07.025. Epub 2018 Jul 21.</citation>
    <PMID>30041010</PMID>
  </results_reference>
  <results_reference>
    <citation>Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DDH, Lipton JH, Kumar R, Messner H, Viswabandya A. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Biol Blood Marrow Transplant. 2018 Nov;24(11):2259-2264. doi: 10.1016/j.bbmt.2018.07.008. Epub 2018 Aug 7.</citation>
    <PMID>30009980</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Research Institute of Pediatrics</investigator_affiliation>
    <investigator_full_name>Yan Yue</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>HSCT, AML， R-AML</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

